Clinical Trial Update: Ferinject® in Patient With Thrombocytosis Secondary to Inflammatory Bowel Disease (IBD) [Phase 2]

View source ↗

Summary

Phase 2 trial of Ferinject (ferric carboxymaltose) for thrombocytosis in inflammatory bowel disease was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Bowel Disease
• Iron Deficiency Anemia
• Thrombocytosis

Drugs mentioned

• Ferinject (ferric carboxymaltose)

Snippet

Sponsor: Vifor Pharma | Conditions: Thrombocytosis, Iron-Deficiency Anemia | Phase 2 | Status: TERMINATED